2 results
Approved WMORecruiting
Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity• Characterize the pharmacokinetics (PK) of bemarituzumab Part 2 (phase 2)Primary:• To evaluate preliminary…
Approved WMOCompleted
Primary objective1. To investigate whether TM38837 attenuates the central effects of THCSecondary objectives2. To explore the effect of TM38837 on THC induced effects on heart rate3. To investigate the effect of 60 mg rimonabant on THC-induced CNS…